Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
Boehringer’s updated results in HER2-mutated lung cancer impress
4 weeks ago
GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer
4 weeks ago
Pharma
Keytruda around head and neck cancer surgery cuts chance of disease coming back
4 weeks ago
Revolution Medicines' KRAS drug shows potential in early cut of lung cancer data
4 weeks ago
J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing
4 weeks ago
FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill
4 weeks ago
Pharma
FDA+
Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval
4 weeks ago
China
Hoping to turn CD47 around with Keytruda combo, ALX Oncology reports two Phase 2 failures
4 weeks ago
Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient
4 weeks ago
People
Cell/Gene Tx
Sanofi's Altuviiio closing in on blockbuster status, Dupixent sales surge
4 weeks ago
Pharma
Ascletis posts puzzling Phase 1 update on obesity pill
4 weeks ago
Akeso reports another Phase 3 win for PD-1xVEGF approach in lung cancer
4 weeks ago
Boehringer taps Dutch biotech for ALT positive cancer pact exceeding $573M in biobucks
4 weeks ago
Deals
Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment
4 weeks ago
Pharma
AstraZeneca, Daiichi eye first-line breast cancer market after Enhertu's early Phase 3 win
4 weeks ago
Pharma
China startup injects CRISPR therapy into the brain for the first time
5 weeks ago
Startups
China
Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study
5 weeks ago
Roivant brings rare disease program closer as Immunovant CEO retires
5 weeks ago
People
Roche discontinues low dose in Huntington’s trial, will switch patients to high dose
Last month
Netherlands pours $1.5B into biotech in pursuit of global leadership ambitions
Last month
Financing
Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes
Last month
CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s
Last month
Glycomine raises $115M to see if it can treat rare glycosylation disorder
Last month
Financing
Startups
Mural Oncology ends clinical development, lays off most workers
Last month
People
First page
Previous page
1
2
3
4
5
6
Next page
Last page